99 related articles for article (PubMed ID: 25845283)
1. Risk of prostate cancer mortality in men with a history of prior cancer.
Dinh KT; Mahal BA; Ziehr DR; Muralidhar V; Chen YW; Viswanathan VB; Nezolosky MD; Beard CJ; Choueiri TK; Martin NE; Orio PF; Sweeney CJ; Trinh QD; Nguyen PL
BJU Int; 2016 Jun; 117(6B):E20-8. PubMed ID: 25845283
[TBL] [Abstract][Full Text] [Related]
2. Early detection of high-grade prostate cancer using digital rectal examination (DRE) in men with a prostate-specific antigen level of <2.5 ng/mL and the risk of death.
Hattangadi JA; Chen MH; D'Amico AV
BJU Int; 2012 Dec; 110(11):1636-41. PubMed ID: 22757982
[TBL] [Abstract][Full Text] [Related]
3. Prognostic impact of synchronous second primary malignancies on the overall survival of patients with metastatic prostate cancer.
Koo KC; Yoo H; Kim KH; Park SU; Han KS; Rha KH; Hong SJ; Yang SC; Chung BH
J Urol; 2015 Apr; 193(4):1239-44. PubMed ID: 25444987
[TBL] [Abstract][Full Text] [Related]
4. Initial management of prostate-specific antigen-detected, low-risk prostate cancer and the risk of death from prostate cancer.
Aizer AA; Chen MH; Hattangadi J; D'Amico AV
BJU Int; 2014 Jan; 113(1):43-50. PubMed ID: 23473327
[TBL] [Abstract][Full Text] [Related]
5. Risk of second primary malignancies among cancer survivors in the United States, 1992 through 2008.
Donin N; Filson C; Drakaki A; Tan HJ; Castillo A; Kwan L; Litwin M; Chamie K
Cancer; 2016 Oct; 122(19):3075-86. PubMed ID: 27377470
[TBL] [Abstract][Full Text] [Related]
6. Advancing age within established Gleason score categories and the risk of prostate cancer-specific mortality (PCSM).
Russo AL; Chen MH; Aizer AA; Hattangadi JA; D'Amico AV
BJU Int; 2012 Oct; 110(7):973-9. PubMed ID: 22954029
[TBL] [Abstract][Full Text] [Related]
7. Risk of second malignancies in patients with early-stage classical Hodgkin's lymphoma treated in a modern era.
LeMieux MH; Solanki AA; Mahmood U; Chmura SJ; Koshy M
Cancer Med; 2015 Apr; 4(4):513-8. PubMed ID: 25620577
[TBL] [Abstract][Full Text] [Related]
8. Risk of breast cancer-related death in women with a prior cancer.
Ji F; Yang CQ; Li XL; Zhang LL; Yang M; Li JQ; Gao HF; Zhu T; Cheng MY; Li WP; Wu SY; Zhong AL; Wang K
Aging (Albany NY); 2020 Apr; 12(7):5894-5906. PubMed ID: 32250967
[TBL] [Abstract][Full Text] [Related]
9. Patient survival and risk of death after prostate cancer treatment in the Brazilian Unified Health System.
Braga SFM; Souza MC; Oliveira RR; Andrade EIG; Acurcio FA; Cherchiglia ML
Rev Saude Publica; 2017 May; 51(0):46. PubMed ID: 28538811
[TBL] [Abstract][Full Text] [Related]
10. Predicting prostate cancer mortality among men with intermediate to high-risk disease and multiple unfavorable risk factors.
Nguyen PL; Chen MH; Catalona WJ; Moul JW; Sun L; D'Amico AV
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):659-64. PubMed ID: 18692327
[TBL] [Abstract][Full Text] [Related]
11. Secondary cancers after intensity-modulated radiotherapy, brachytherapy and radical prostatectomy for the treatment of prostate cancer: incidence and cause-specific survival outcomes according to the initial treatment intervention.
Zelefsky MJ; Pei X; Teslova T; Kuk D; Magsanoc JM; Kollmeier M; Cox B; Zhang Z
BJU Int; 2012 Dec; 110(11):1696-701. PubMed ID: 22889401
[TBL] [Abstract][Full Text] [Related]
12. Incidence of second malignancies in prostate cancer patients treated with low-dose-rate brachytherapy and radical prostatectomy.
Hamilton SN; Tyldesley S; Hamm J; Jiang WN; Keyes M; Pickles T; Lapointe V; Kahnamelli A; McKenzie M; Miller S; Morris WJ
Int J Radiat Oncol Biol Phys; 2014 Nov; 90(4):934-41. PubMed ID: 25240272
[TBL] [Abstract][Full Text] [Related]
13. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy.
D'Amico AV; Renshaw AA; Sussman B; Chen MH
JAMA; 2005 Jul; 294(4):440-7. PubMed ID: 16046650
[TBL] [Abstract][Full Text] [Related]
14. Cancer incidence after localized therapy for prostate cancer.
Moon K; Stukenborg GJ; Keim J; Theodorescu D
Cancer; 2006 Sep; 107(5):991-8. PubMed ID: 16878323
[TBL] [Abstract][Full Text] [Related]
15. Italian cancer figures, report 2013: Multiple tumours.
AIRTUM Working Group
Epidemiol Prev; 2013; 37(4-5 Suppl 1):1-152. PubMed ID: 24259384
[TBL] [Abstract][Full Text] [Related]
16. Androgen deprivation therapy and the risk of death from prostate cancer among men with favorable or unfavorable intermediate-risk disease.
Keane FK; Chen MH; Zhang D; Moran BJ; Braccioforte MH; D'Amico AV
Cancer; 2015 Aug; 121(16):2713-9. PubMed ID: 25925789
[TBL] [Abstract][Full Text] [Related]
17. Multiple primary malignant neoplasms associated with prostate cancer in 312 consecutive cases.
Kawakami S; Fukui I; Yonese J; Ueda T; Ohno Y; Tsuzuki M; Kawai T
Urol Int; 1997; 59(4):243-7. PubMed ID: 9444743
[TBL] [Abstract][Full Text] [Related]
18. Differences according to socioeconomic status in the management and mortality in men with high risk prostate cancer.
Berglund A; Garmo H; Robinson D; Tishelman C; Holmberg L; Bratt O; Adolfsson J; Stattin P; Lambe M
Eur J Cancer; 2012 Jan; 48(1):75-84. PubMed ID: 21852113
[TBL] [Abstract][Full Text] [Related]
19. Impact of initial local therapy on survival in men later receiving chemotherapy for prostate cancer: a population-based, propensity-weighted multivariable analysis.
Zabell JR; Adejoro O; Jarosek SL; Elliott SP; Konety BR
World J Urol; 2016 Oct; 34(10):1397-403. PubMed ID: 26914817
[TBL] [Abstract][Full Text] [Related]
20. Prostate cancer survivors: Risk and mortality in second primary cancers.
Chattopadhyay S; Zheng G; Hemminki O; Försti A; Sundquist K; Hemminki K
Cancer Med; 2018 Nov; 7(11):5752-5759. PubMed ID: 30277023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
